AZN — ASTRAZENECA PLC
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 901832 ·
United Kingdom
Last close
$158.50
Market Cap
$245.82B
52W High
$196.41
52W Low
$153.41
ADV30
3,670,843
Next earnings
2026-10-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 15,384,000,000 | 12,861,000,000 | 3,164,000,000 | 2,507,000,000 | 115,833,000,000 | 4,893,000,000 | 65,463,000,000 |
| Mar 2026 | 15,288,000,000 | 12,610,000,000 | 4,246,000,000 | 3,080,000,000 | 114,015,000,000 | 7,560,000,000 | 66,631,000,000 |
| Dec 2025 | 15,503,000,000 | 12,385,000,000 | 2,978,000,000 | 2,326,000,000 | 114,074,000,000 | 5,711,000,000 | 65,355,000,000 |
| Sep 2025 | 15,191,000,000 | 12,390,000,000 | 3,583,000,000 | 2,533,000,000 | 114,456,000,000 | 8,143,000,000 | 68,485,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$13,700,000,000
Investing CF
$-8,151,000,000
Financing CF
$-7,680,000,000
CapEx
$-7,656,000,000
Dividends Paid
$-4,902,000,000
Buybacks
—
EPS Diluted TTM
$6.64
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$12,592,000,000
Inventory
$6,932,000,000
Receivables
—
ST Investments
$75,000,000
EBIT TTM
$14,332,000,000
Pretax Income TTM
$12,586,000,000
Interest Exp TTM
$1,746,000,000
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$61,366,001,664
EBITDA
$19,904,000,000
Free Cash Flow
$4,905,375,232
Enterprise Value
$273,290,493,952
Total Cash
$4,968,000,000
Total Debt
$32,349,999,104
Shares Out
1,550,885,842
Trailing EPS
$6.67
Book Value
$32.43
ROE
22.0%
ROA
8.0%
Div Yield
2.01%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 58,739,000,000 | 13,327,000,000 | 10,225,000,000 | 114,074,000,000 | 65,355,000,000 | — | 14,575,000,000 |
| Dec 2024 | 54,073,000,000 | 10,251,000,000 | 7,035,000,000 | 104,035,000,000 | 63,164,000,000 | — | 11,861,000,000 |
| Dec 2023 | 45,811,000,000 | 8,722,000,000 | 5,955,000,000 | 101,119,000,000 | 61,953,000,000 | — | 10,345,000,000 |
| Dec 2022 | 44,351,000,000 | 4,512,000,000 | 3,288,000,000 | 96,483,000,000 | 59,425,000,000 | — | 9,808,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$11.58
Max Pain — expiry 2026-08-21
max pain strike: $160.00 · spot: $157.13 · call oi: 11,347 · put oi: 4,794
Expected Move to 2026-08-21:
±$5.38
(3.42%) —
implied range
$151.76 –
$162.51
· ATM straddle on $155.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NVS | NOVARTIS AG | $289.52B | $152.32 | — |
| NVSEF | NOVARTIS AG | $300.12B | $157.90 | — |
| ABT | ABBOTT LABORATORIES | $193.18B | $110.91 | — |
| MRK | Merck & Co., Inc. | $327.94B | $132.92 | — |
| NVO | NOVO NORDISK A S | $153.38B | $46.39 | — |
News headlines (Yahoo Finance, 1h cache)
How AstraZeneca’s $400bn deal unravelled
2026-08-12 04:00 · Yahoo
Do Options Traders Know Something About AstraZeneca Stock We Don't?
2026-08-11 14:11 · Yahoo
Can AstraZeneca (AZN) Reach Its $80 Billion Revenue Goal Despite Clinical Setbacks?
2026-08-10 23:44 · Yahoo
The 20-year exodus hollowing out the London stock market
2026-08-07 05:00 · Yahoo
Jim Cramer Recommends Goldman Sachs and Morgan Stanley to Profit From Accelerating M&A Deals
2026-08-11 05:43 · Yahoo
The Advertising Research Foundation Announces 2026 ARF David Ogilvy Awards Finalists
2026-08-13 15:02 · Yahoo
Can Keytruda Sustain Merck's Growth in the Second Half of 2026?
2026-08-13 14:00 · Yahoo
AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn’t Buy This Merger Talk
2026-08-11 19:34 · Yahoo
Hedge Funds are Bullish on AstraZeneca PLC (AZN)
2026-08-11 14:04 · Yahoo
MRK Stock Up 5.6% in a Month as Estimates Fall: Buy, Hold or Sell?
2026-08-11 13:48 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.